(Q37975682)

English

Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials

scientific article published on 16 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

0 references

Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

0 references

circulatory system

1 reference

based on heuristic

inferred from title

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

author name string

Yu Pan

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Li Li Guo

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Ling Ling Cai

3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Xiao Juan Zhu

4

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Jin Lian Shu

5

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Xiao Li Liu

6

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Hui Min Jin

7

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

publication date

16 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

British Journal of Nutrition

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

108

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

400-407

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

The clinical implications of endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Homocysteine lowering with folic acid and B vitamins in vascular disease

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance.

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

"New" cardiovascular risk factors in patients with chronic kidney disease: role of folic acid treatment

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Hyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12.

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients.

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Ant

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients.

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Cancer incidence and mortality after treatment with folic acid and vitamin B12.

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Elevated homocysteine serum level is associated with low enrichment of homocysteine in coronary arteries of patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Treatment with different doses of folic acid in haemodialysis patients: effects on folate distribution and aminothiol concentrations

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

21 January 2018

Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

7 January 2021

based on heuristic

inferred from DOI database lookup

Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

7 January 2021

based on heuristic

inferred from DOI database lookup

Dialysis kinetics of homocysteine and reactive oxygen species

1 reference

https://api.crossref.org/works/10.1017%2FS0007114511007033

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1017/S0007114511007033

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37975682&oldid=1735768752"